Verition Fund Management
CMPX icon

Verition Fund Management’s Compass Therapeutics CMPX Stock Holding History

Verition Fund Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-32,245
Closed -$61.3K – 3660
2025
Q1 		$61.3K Buy
+32,245
New +$85.7K ﹤0.01% 3188
2023
Q4 		– Sell
-15,515
Closed -$30.6K – 2380
2023
Q3 		$30.6K Buy
+15,515
New +$38.4K ﹤0.01% 2212
2023
Q2 		– Sell
-23,062
Closed -$75.4K – 2243
2023
Q1 		$75.4K Buy
+23,062
New +$90.5K ﹤0.01% 1934

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management's CMPX Position: Q2 2025 in Review

Verition Fund Management sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 32,245 shares — an estimated $61.3K sold.

Verition Fund Management first reported a position in CMPX in Q1 2023 and held it in 3 quarters. The position peaked at $75.4K in Q1 2023. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • Verition Fund Management reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 32,245 Compass Therapeutics shares in Q2 2025, an estimated $61.3K.
  • Verition Fund Management first reported a position in Compass Therapeutics in Q1 2023 and held it in 3 quarters.
  • Verition Fund Management's Compass Therapeutics position peaked at $75.4K in Q1 2023.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.